כסף מזומן למניה Sangamo BioSciences (SGMO)

Sangamo Therapeutics (SGMO) relies on the B2B integration of its AI platform into the R&D chains of tech giants, ensuring the precision of DNA correction within organs. Cash per share for the period on GURU.Markets demonstrates liquidity, where the value 0.05 serves as the baseline metric. This supports the company's expansion into the rare pathology therapy segment through a strategic alliance with partners.
פילוחי מדדים מקיפים ואנליטיקה עבור Sangamo Therapeutics Inc. (SGMO)

The metric is calculated by dividing the total volume of liquid assets by the number of shares outstanding, determining the actual value of "liquid" cash per share of capital. For Sangamo Therapeutics (SGMO), which invests in biolab security and DNA editing, this cash per share reserve serves as an indicator of financial stability during the implementation of long-term clinical developments.